Answers are grounded in this paper and cite their sources.
Background Antibiotic-associated diarrhea (AAD) affects 5–35% of children receiving antibiotics. Probiotic efficacy is strain-specific, and uncertainty remains regarding optimal strains, doses, and populations. Methods We searched PubMed, Cochrane Library, ClinicalTrials.gov, Europe PMC, and ScienceDirect on 28 June 2026. Eligible studies were any original research design (randomized trials, non-randomized interventional, or observational studies) of children (0–18 years) receiving systemic antibiotics, comparing probiotics with placebo or no probiotic, and reporting AAD incidence. Risk of bias was assessed using RoB 2, ROBINS-I V2, and JBI tools; studies at critical or serious risk were excluded. Certainty was evaluated using GRADE. Given substantial heterogeneity, a structured narrative synthesis was performed; no pooled estimate was calculated. Results Of 521 records, 15 studies (3,489 children) met inclusion criteria; all were randomized controlled trials after quality appraisal. Probiotics reduced AAD risk in 10 of 15 studies (67%), with significant reductions in 7 (47%). Saccharomyces boulardii showed a large effect in one trial (RR 0.20, 95% CI 0.07–0.50). Lactobacillus rhamnosus GG showed consistent direction of benefit across four trials but variable magnitude (RR 0.29–0.34 in the three trials reporting RRs). L. reuteri DSM 17938 showed benefit in one large outpatient trial (RR 0.47, 95% CI 0.30–0.73) but null effects in two inpatient trials. Multi-strain mixtures yielded mixed results. Doses ≥10 9 CFU/day and age 6–24 months were associated with greater benefit. No serious probiotic-attributable adverse events occurred. Over 10 distinct AAD definitions precluded meta-analysis. GRADE certainty was Low to Moderate. Conclusions Effects are strain- and context-dependent; routine use is not supported. Targeted use of S. boulardii or L. rhamnosus GG at ≥10 9 CFU/day may be considered for high-risk children, particularly those aged 6–24 months on broad-spectrum antibiotics. Registration: Not registered in PROSPERO; acknowledged as a limitation.
No takes yet. Share an insight, caveat, or question.
Mithani et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: